Skip to main content
. 2022 Oct 11;13:961805. doi: 10.3389/fimmu.2022.961805

Table 2.

Summary of major marketed and clinically reported small molecule immunotherapy drugs (Up to March 2022).

Target Name Structure Company Highest Development Phases
PD-L1/VISTA CA-170 graphic file with name fimmu-13-961805-i001.jpg Aurigene, Curis Phase II (NCT01288911)
PD-L1 INCB-086550 graphic file with name fimmu-13-961805-i002.jpg Incyte Phase II (NCT04629339)
PD-L1 GS-4224 graphic file with name fimmu-13-961805-i003.jpg Gliead Phase 1b/2 (NCT04049617)
PD-1 MX-10181 undisclosed Maxinovel Phase I (NCT04122339)
IDO1 BMS-986205 graphic file with name fimmu-13-961805-i004.jpg Bristol-Myers Squibb Phase III (NCT03661320)
IDO1 INCB-024360 graphic file with name fimmu-13-961805-i005.jpg Incyte Phase III (NCT02752074)
STING ADU-S100 graphic file with name fimmu-13-961805-i006.jpg Aduro, Novartis Phase II (NCT03937141)
STING MK-1454 graphic file with name fimmu-13-961805-i007.jpg Merck Phase II (NCT04220866)
A2AR AZD4635 graphic file with name fimmu-13-961805-i008.jpg AstraZeneca Phase II (NCT04089553)
A2AR NIR178 graphic file with name fimmu-13-961805-i009.jpg Novartis Phase II (NCT03207867)
CXCR2 AZD5069 graphic file with name fimmu-13-961805-i010.jpg AstraZeneca Phase II (NCT03177187)
CXCR4 Mavorixafor graphic file with name fimmu-13-961805-i011.jpg X4 Pharmaceuticals Phase III (NCT03995108)
CCR2/5 BMS-813160 graphic file with name fimmu-13-961805-i012.jpg Bristol-Myers Squibb Phase II (NCT03184870)
TLR7 Imiquimod graphic file with name fimmu-13-961805-i013.jpg 3M Pharmaceuticals Marketed
TLR8 Motolimod graphic file with name fimmu-13-961805-i014.jpg Array Pharma, Celgene Phase I/II (NCT02431559)
ARG INCB001158 graphic file with name fimmu-13-961805-i015.jpg Calithera Biosciences, Incyte Phase I/II (NCT02903914)